Johnson & Johnson (J&J) subsidiary Janssen Pharmaceutical has signed an agreement with Emergent BioSolutions for manufacturing services for its lead investigational Covid-19 vaccine candidate.
The vaccine programme builds on Janssen’s AdVac and PER.C6 technologies. Under the agreement, worth around $135m, Emergent will offer drug substance manufacturing services using its molecule-to-market CDMO offering.
The services will support investments from J&J starting this year. Emergent will reserve some large-scale manufacturing capacity to prepare for commercial manufacturing of the adenovirus-based Covid-19 vaccine beginning next year.